Your session is about to expire
← Back to Search
Ruxolitinib for Squamous Cell Carcinoma
Study Summary
This trial is testing a new cancer treatment and whether it is safe for people who have had solid organ transplants.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 149 Patients • NCT02038036Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are researchers still enrolling participants for this clinical trial?
"According to the most recent update, this clinical trial posted on 7/8/2021 is still recruiting patients."
For what medical condition is Ruxolitinib commonly prescribed?
"Ruxolitinib is most often used to treat polycythemia vera. However, it has also been found to ameliorate symptoms in patients with hydroxyurea resistance or intolerance, and those suffering from primary myelofibrosis."
What other studies have there been on Ruxolitinib's effects?
"Ruxolitinib was first studied in an NIH-sponsored clinical trial 18 years ago. Since then, there have been a total of 92 completed trials involving this medication. Right now, there are 99 active trials being conducted worldwide; many of these studies are based out of New york City."
Has Ruxolitinib received regulatory approval from the FDA?
"Ruxolitinib's safety is based on Phase 2 clinical trial data, which means that while there is evidence that it is safe, there is no guarantee of its efficacy."
Share this study with friends
Copy Link
Messenger